Page 160 - rcv31n3.vp

Prevención cardiovascular en el diabético Revista Uruguaya de Cardiología
Washington Vignolo, Bernardo Layerle Volumen 31 | nº 3 | Diciembre 2016

109. ACCORD Study Group. Effects of combination li- diovascular events. N Engl J Med. 2015 Apr
pid therapy in type 2 diabetes mellitus. N Engl J Med. 16;372(16):1500-9. doi:10.1056/NEJMoa1500858.
2010 April 29;362(17):1563-74.
114. Gaede P, Vedel P, Parving HH, Pedersen O.
doi:10.1056/NEJMoa1001282.
Intensified multifactorial intervention in patients
110. AIM-HIGH Investigators. Niacin in patients with with type 2 diabetes mellitus and microalbuminuria:
low HDL cholesterol levels receiving intensive statin the Steno type 2 randomised study. Lancet. 1999 Feb
therapy. N Engl J Med. 2011 Dec 15;365(24):2255-67. 20;353(9153):617-22.
doi:10.1056/NEJMoa1107579. doi:10.1016/S0140-6736(98)07368-1.
115. Gaede P, Lund-Andersen H, Parving H-H, Pe-
111. HPS2-THRIVE Collaborative Group. Effects of
dersen O. Effect of a multifactorial intervention on
extended-release niacin with laropiprant in high-risk
mortality in type 2 diabetes. N Engl J Med. 2008 Feb
patients. N Engl J Med. 2014 Jul 17;371(3):203-12.
7;358(6):580-91. doi:10.1056/NEJMoa0706245.
doi:10.1056/NEJMoa1300955.
116. Yang Y, YaoJ,DuJL, BaiR,Sun LP,Sun GH,et
112. Robinson JG, Farnier M, Krempf M, Bergeron al. Primary prevention of macroangiopathy in patients
J, Luc G, Averna M,et al; ODYSSEY LONG with short-duration type 2 diabetes by intensified mul-
TERM Investigators. Efficacy and safety of aliro- tifactorial intervention: seven-year follow-up of diabe-
cumab in reducing lipids and cardiovascular events. tes complications in Chinese. Diabetes Care. 2013
N Engl J Med. 2015 Apr 16;372(16):1489-99. Apr;36(4):978-84. doi:10.2337/dc12-0227.
doi:10.1056/NEJMoa1501031.
117. Howard BV, Roman MJ, Devereux RB, Fleg JL,
113. Sabatine MS, Giugliano RP, Wiviott SD, Raal Galloway JM, Henderson JA, et al. Effect of lo-
FJ, Blom DJ, Robinson J, et al; Open-Label wer targets for blood pressure and LDL cholesterol
Study of Long-Term Evaluation against LDL on atherosclerosis in diabetes: the SANDS randomi-
Cholesterol (OSLER) Investigators. Efficacy zed trial. JAMA. 2008 Apr 9;299(14):1678-89.
and safety of evolocumab in reducing lipids and car- doi:10.1001/jama.299.14.1678.

504